Physiology and function of the erythropoietin receptor

Current Opinion in Hematology

Volumn 5, Issue 3, 1998, Pages 171-176

  Yoshimura, Akihiko ^a   Misawa, Hiroyuki ^a  

^a KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; STAT5 PROTEIN; TYROSINE;

BURST FORMING UNIT E; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIMERIZATION; ENZYME ACTIVATION; ERYTHROCYTOSIS; ERYTHROID CELL; ERYTHROPOIESIS; GENE DISRUPTION; GENE MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0031876654     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199805000-00004     Document Type: Review

References (79)

1. O'Shea JJ: Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet? Immunity 1997, 7:1-11. Excellent review on JAK and STAT and the problems remaining, especially in immunology.
2. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN: JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
3. Darnell JE. STATs and gene regulation. Science 1997, 277: 1630-1635. Excellent update review on STATs.
4. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A: Interleukin 2 (IL2) and erythropoietin (EPO) activate STAT5/MGF via distinct pathways. EMBO J 1995, 14:2527-2535.
5. Yoshimura A, Longmore G, Lodish HF: Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 1990, 348:647-649.
6. Watowich SS, Hilton DJ, Lodish HF: Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol Cell Biol 1994, 14:3535-3549.
7. Barber DL, DeMartino JC, Showers MO, D'Andrea AD: A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation. Mol Cell Biol 1994, 14:2257-2265.
8. Iwatsuki K, Endo T, Misawa H, Yokouchi M, Matsumoto A, Ohtsubo M, Mori KJ, Yoshimura A: STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. J Biol Chem 1997, 272:8149-8152. The EGFR-EPOR chimera can transmit erythroid differentiation signals, indicating that dimerization of the cytoplasmic domain of the EPOR is sufficient for differentiation signal. This paper indicates that Tyrosine343 and Tyrosine401, which are STAT5 binding sites, are important for EPOR mediated erythroid differentiation signal in ELM-1 erythroleukemia cells.
9. Sharlow ER, Pacifici R, Crouse J, Batac J, Todokoro K, Wojchowski DM: Hematopoietic cell phosphatase negatively regulates erythropoietin-induced hemoglobinization in erythroleukemic SKT6 cells. Blood 1997, 90:2175-2187. The EGFR-EPOR chimera can transmit erythroid differentiation signals, indicating that dimerization of the cytoplasmic domain of the EPOR is sufficient for differentiation signal. This paper suggests a negative regulatory effect of HCP on EPOR-mediated erythroid differentiation signals.
10. Luo K, Lodish HF: Signaling by chimeric erythropoietin-TGF-beta receptors: Homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. EMBO J 1996, 15:4485-4496.
11. Schneider H, Chaovapong W, Matthews DJ, Karkaria C, Cass RT, Zhan H, Boyle M, Lorenzini T, Elliott SG, Giebel LB: Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 1997, 89:473-482.
12. Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliot G: Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem 1996, 271:24691-24697.
13. Blau CA, Peterson KR, Drachman JG, Spencer DM: A proliferation switch for genetically modified cells. Proc Natl Acad Sci U S A 1997, 94:3076-3081.
14. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J: Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry 1996, 35:1681-1691.
15. Chiba T, Nagata Y, Machide M, Kishi A, Amanuma H, Sugiyama M, Todokoro K: Tyrosine kinase activation through the extracellular domains of cytokine receptors. Nature 1993, 362:646-648.
16. Chiba T, Nagata Y, Kishi A, Sakamaki K, Miyajima A, Yamamoto M, Engel JD, Todokoro K: Induction of erythroid-specific gene expression in lymphoid cells. Proc Natl Acad Sci U S A 1993, 90:11593-11597.
17. Yoshimura A: Second subunit of Epo receptor? Nature 1994, 372:137-138. This letter points out the problem of the system using Ba/F3 cells, in which the endogenous EPOR can be expressed.
18. Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW, Dower WJ: Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol 1997, 15:1261-1265.
19. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-464. Striking finding that a small peptide can be an agonist of EPO.
20. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science 1996, 273:464-471. Three-dimensional structure of the EPOR extracellular domain with peptide agonist.
21. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, et al.: Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997, 276:1696-1699.
22. Wu H, Liu X, Jaenisch R, Lodish HF: Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83:59-67.
23. Lin CS, Lim SK, D'Agati V, Costantini F: Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996, 10:154-164.
24. Kieran MW, Perkins AC, Orkin SH, Zon LI: Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc Natl Acad Sci U S A 1996, 93:9126-9131.
25. Socolovsky M, Dusanter-Fourt I, Lodish HF: The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J Biol Chem 1997, 272:14009-14012. Erythroid colony formation by truncated EPOR containing Tyrosine 343 and prolactin receptor.
26. Joneja B, Wojchowski DM: Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain. J Biol Chem 1997, 272:11176-11184.
27. Damen JE, Krystal G: Early events in erythropoietin-induced signaling. Exp Hematol 1996, 24:1455-1459.
28. Miura O, Miura Y, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N: Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 1994, 84:4135-4141.
29. Ren HY, Komatsu N, Shimizu R, Okada K, Miura Y: Erythropoietin Induces tyrosine phosphorylation and activation of phospholipase C-gamma 1 in a human erythropoietin-dependent cell line. J Biol Chem 1994, 269:19633-19638.
30. Damen JE, Cutler RL, Jiao H, Yi T, Krystal G: Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (Pl) 3-kinase and for EpR-associated Pl 3-kinase activity. J Biol Chem 1995, 270:23402-23408.
31. Tauchi T, Damen JE, Toyama K, Feng GS, Broxmeyer HE, Krystal G: Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis. Blood 1996, 87:4495-4501.
32. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW, Krystal G: The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci U S A 1996, 93:1689-1693.
33. Damen JE, Liu L, Cutler RL, Krystal G. Erythropoietin stimulates the tyrosine phosphorylation of She and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein. Blood 1993, 82:2296-2303.
34. Barber DL, Mason JM, Fukazawa T, Reedquist KA, Druker BJ, Band H, D'Andrea AD: Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood 1997, 89:3166-3174.
35. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A: A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995, 14:2816-2826. CIS is a cytokine-inducible gene containing SH2 domain. It binds to the activated EPO and interleukin-3 receptors and negatively regulates their functions.
36. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF: Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995, 80:729-738.
37. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G: Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 1995, 14:5557-5568.
38. Quelle FW, Wang D, Nosaka T, Thierfelder WE, Stravopodis D, Weinstein Y, Ihle JN: Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol 1996, 16:1622-1631.
39. Gobert S, Chretien S, Gouilleux F, Muller O, Pallard C, Dusanter-Fourt I, Groner B, Lacombe C, Gisselbrecht S, Mayeux P: Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO J 1996, 15:2434-2441.
40. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF: Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci U S A 1996, 93:8324-8328.
41. Sawyer ST, Penta K: Association of JAK2 and STAT5 with erythropoietin receptors: Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem 1996, 271:32430-32437.
42. Damen JE, Liu L, Wakao H, Miyajima A, Rosten P, Jefferson AB, Majerus PW, Krosl J, Humphries RK, Krystal G: The role of erythropoietin receptor tyrosine phosphorylation in erythropoietin-induced proliferation. Leukemia 1997, 11, Suppl 3:423-425.
43. Yin T, Shen R, Feng GS, Yang YC: Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases. J Biol Chem 1997, 272:1032-1037.
44. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T: Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 1996, 16:6985-6992.
45. Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T: An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 1997, 14:751-761.
46. Nagata Y, Moriguchi T, Nishida E, Todokoro K: Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 1997, 90:929-934.
47. Barber DL, Corless CN, Xia K, Roberts TM, D'Andrea AD: Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells. Blood 1997, 89:55-64.
48. Nagata Y, Nishida E, Todokoro K: Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood 1997, 89:2664-2669.
49. Verdier F, Chretien S, Billat C, Gisselbrecht S, Lacombe C, Mayeux P: Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2. An alternate pathway for erythropoietin induced phosphatidylinositol 3-kinase activation. J Biol Chem 1997, 272:26173-26178.
50. Tilbrook PA, Ingley E, Williams JH, Hibbs ML, Klinken SP: Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J 1997, 16:1610-1619. Excellent demonstration of an essential role of lyn kinase in EPO-induced differentiation of J2E erythroid cells. Association of lyn with the EPOR is also shown.
51. Wu H, Klingmuller U, Besmer P, Lodish HF: Interaction of the erythropoietin and stem-cell-factor receptors. Nature 1995, 377:242-246.
52. Wu H, Klingmuller U, Acurio A, Hsiao JG, Lodish HF: Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc Natl Acad Sci U S A 1997, 94:1806-1810.
53. Joneja B, Chen H-C, Seshasayee D, Wrentmore AL, Wojchowski DM: Mechanisms of stem cell factor and erythropoietin proliferative cosignaling in FDC2-ER cells. Blood 1997, 90:3533-3545.
54. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, et al.: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
55. Grusby MJ: Stat4- and Stat6-deficient mice as models for manipulating T helper cell responses. Biochem Soc Trans 1997, 25:359-360.
56. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997, 94:3801-3804.
57. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW: Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997, 94:7239-7244.
58. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997, 11:179-186.
59. Feldman GM, Rosenthal LA, Liu X, Hayes MP, Wynshaw-Boris A, Leonard WJ, Hennighausen L, Finbloom DS: STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 1997, 90:1768-1776.
60. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996, 15:3651-3658.
61. Shimozaki K, Nakajima K, Hirano T, Nagata S: Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 1997, 272:25184-25189. STAT3 is demonstrated to be important for G-CSF-induced differentiation signals.
62. Boeuf H, Hauss C, Graeve FD, Baran N, Kedinger C: Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells. J Cell Biol 1997, 138:1207-1217.
63. Wakao H, Chida D, Damen JE, Krystal G, Miyajima A: A possible involvement of Stat5 in erythropoietin-induced hemoglobin synthesis. Biochem Biophys Res Commun 1997, 234:198-205.
64. Chretien S, Varlet P, Verdier F, Gobert S, Cartron JP, Gisselbrecht S, Mayeux P, Lacombe C: Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO J 1996, 15:4174-4181.
65. Pless M, Norga K, Carroll M, Heim MH, D'Andrea AD, Mathey-Prevot B: Receptors that induce erythroid differentiation of Ba/F3 cells: Structural requirements and effect on STAT5 binding. Blood 1997, 89:3175-3185.
66. Ishiguro K, Sartorelli AC: Clonal variability in beta-globin mRNA content in an interleukin-3-dependent bone marrow cell line transfected with the erythropoietin receptor before and after stimulation with erythropoietin. Blood 1997, 90:2273-2281.
67. Matsumoto A, Masuhara M. Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyjima A, Yoshimura A: CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 actiation. Blood 1997, 89:3148-3154. CIS is shown to be a target of STAT5 and negative regulator of STAT5.
68. Yoshimura A, Ichihara M, Kinjyo I, Moriyama M, Copeland NG, Gilbert DJ, Jenkins NA, Hara T, Miyajima A: Mouse oncostatin M: An immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J 1996, 15:1055-1063.
69. Nakamura Y, Tokumoto Y, Nakauchi H: Role of a truncated erythropoietin receptor for erythroid differentiation. Biochem Biophys Res Commun 1996, 218:205-209.
70. Chiba S, Takahashi T, Takeshita K, Minowada J, Yazaki Y, Ruddle FH, Hirai H: Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera. Blood 1997, 90:97-104.
71. Furukawa T, Narita M, Sakaue M, Otsuka T, Kuroha T, Masuko M, Azegami T, Kishi K, Takahashi M, Utsumi J, et al.: Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor. Br J Haematol 1997, 99:222-227.
72. Arcasoy MO, Degar BA, Harris KW, Forget BG: Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997, 89:4628-4635.
73. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prichal JT: Two new EPO receptor mutations: Truncated EPO receptors are most frequently asociated with primary familial and congenital polycythemias. Blood 1997, 90:2057-2061.
74. Endo AT, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al.: A new protein containing an SH2 domain that Inhibits JAK kinases. Nature 1997, 387:921-924. Finding of a new CIS family member, JAB, which binds to and inhibits JAK kinases.
75. Starr R, Willson TA, Viney EM, Murray U, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921. Cloning of the same gene described in Endo et al. (Nature 1997, 387:921-924).
76. Starr R, Willson TA, Viney EM, Murray U, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921. Cloning of the same gene described in Endo et al. (Nature 1997, 387:921-924).
77. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al.: Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929. Cloning of the same gene described in Endo et al. (Nature 1997, 387:921-924).
78. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al.: Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929. Cloning of the same gene described in Endo et al. (Nature 1997, 387:921-924).
79. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, et al.: Cloning and characterization of Novel CIS family genes. Biochem Biophys Res Commun 1997, 239:439-446. Description of the CIS family genes, which are a new regulators of cytokine signaling.